在治疗过度活跃的膀治疗中使用和持续使用β3-腺素受体激活剂
Naoki Wada1, Kotona Miyauchi1, Taichiro Ishimaru1
1Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, Japan.
概括
这项关于过度活性膀 (OAB) 治疗的研究发现,vibegron可能比mirabegron提供更好的持久性. 在这些β3-上腺激动剂之间切换可以帮助有效地管理OAB.
科学领域:
- 药理学 药理学是指药理学的学科.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 现实世界的证据.
背景情况:
- 过活性膀 (OAB) 影响全球数百万人,需要有效的治疗选择.
- 米拉贝格伦和维贝格伦是用于OAB管理的β3-上腺素激动剂.
- 了解现实世界的使用和持续性对于优化OAB治疗至关重要.
研究的目的:
- 在OAB患者中比较mirabegron和vibegron的实际使用模式.
- 评估和比较mirabegron和vibegron的药物持续率.
- 在mirabegron和vibegron之间切换时评估β3-上腺激素激动剂治疗的持久性.
主要方法:
- 对接受mirabegron或vibegron治疗的OAB患者的回顾性审查 (2022年8月至2024年12月).
- 评估个体药物持续性 (持续率I).
- 在转换药物后评估整体β3-上腺激素激剂持久性 (持久率II).
主要成果:
- 包括192名患者:其中128名 (66.7%) 是mirabegron,64名 (33.3%) 是vibegron.
- 中位持续率I:mirabegron的11个月;vibegron没有达到.
- 对于mirabegron (40.7%) 和vibegron (17.6%) 的更高的中止率,许多人转向了替代的β3激动剂.
结论:
- 更高的mirabegron中止可能与vibegron的可用性有关.
- 补充使用mirabegron和vibegron可以增强OAB管理.
- 对β3-上腺激素激动剂切换模式的进一步研究是有必要的.
相关概念视频
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.3K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.3K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
01:18Adrenergic Agonists: Therapeutic Classification
1.4K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.4K
01:30Adrenergic Agonists: Therapeutic Uses
1.6K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.6K
01:26Adrenergic Receptors: β Subtype
3.4K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.4K
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.5K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.5K